Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

ALPHAGAN OPHTHALMIC SOLUTION 0.2% [SIN09788P]

Active ingredients: BRIMONIDINE TARTRATE

View product's general information
Last updated 16 September 2026

Product Info

ALPHAGAN OPHTHALMIC SOLUTION 0.2%

[SIN09788P]

Product information

Active Ingredient and Strength

BRIMONIDINE TARTRATE - 0.2%

Dosage Form

SOLUTION

Manufacturer and Country

ALLERGAN PHARMACEUTICALS IRELAND - IRELAND

Registration Number

SIN09788P

Licence Holder

ABBVIE PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

S01EA05

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

INDICATIONS AND USAGE
ALPHAGAN® is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The IOP lowering efficacy of ALPHAGAN® ophthalmic solution diminishes over time in some patients. This loss of effect appears with a variable time of onset in each patient and should be closely monitored.

Dosing

DOSAGE AND ADMINISTRATION
The recommended dose is one drop of ALPHAGAN® in the affected eye(s) two times daily. For those patients whose IOP peaks in the afternoon or need additional IOP control, an additional drop of brimonidine in the afternoon can be added.

If more than one topical ophthalmic drug is to be used, the different drugs should be instilled at least 5 minutes apart.

Contraindications

CONTRAINDICATIONS
ALPHAGAN® is contraindicated in patients with hypersensitivity to brimonidine tartrate or any component of this medication. It is also contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy and contraindicated in neonates and infants (children under the age of 2 years).